Adma Biologics Profit Margin

As of the most recent data (March 2026), ADMA shows a profit margin of 32.43%. That compares with 45.01% in the prior-year period — down 27.9% year over year. That is above the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADMA's profit margin is now 32.43% (was 45.01%) — a 27.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Adma Biologics is outperforming or lagging.

The Healthcare sector average profit margin is about 15.58%. Adma Biologics is at 32.43%, which is higher that average. That is roughly 108.1% above the sector mean. Use the comparison chart on this page to see how ADMA stacks up against individual peers as well.

That compares with 45.01% in the prior-year period — down 27.9% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Adma Biologics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Adma Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 32.43%) with ownership activity and broader fundamentals.